Hubungan Kadar CA-125 Praoperatif terhadap Prognosis Survival Penderita Kanker Ovarium Epitelial di RSUP Dr.Sardjito

https://doi.org/10.22146/jkr.37949

Herlina Pradjatmo(1*), Rukmono Siswishanto(2), Shinta Prawitasari(3)

(1) Departemen Obstetri dan Ginekologi, FK-KMK, UGM
(2) Departemen Obstetri dan Ginekologi, FK-KMK, UGM
(3) Departemen Obstetri dan Ginekologi, FK-KMK, UGM
(*) Corresponding Author

Abstract


Background: CA-125 level increases in 50% of patients with stage I, 90% of patients with stage II, 92% of patients with stage III and 94% of patients with stage IV ovarian cancer. CA-125 level were not a diagnostic tool to detect ovarian cancer, however it was useful to monitor the progressive of disease and as a prognostic marker.

Objectives: The aim of this study is to prove whether CA-125 level before surgery in ovarian cancer patients at Dr. Sardjito Hospital as well as a factor that correlates to the survival prognosis of those patients.

Method: This research used cohort retrospective study at Dr. Sardjito Hospital Yogyakarta.

Result and Discussion: As much as 71 ovarian cancer patients which had been included in this research with inclusion and exclusion criteria. Subjects were divided into two groups. One group was for patients with low CA-125 level (≤35 U/ml) as much as 18 subjects and another group was for patients with high CA-125 level (>35 U/ml) as much as 53 subjects. The result of a bivariate analysis with an independent survival analysis (Cox’s Regression) was the stage of disease (p=0.005, HR 4.827, CI 95% 1.623 – 14.355) and residual tumour (p=0.029, HR 2.605, CI 95% 1.101 – 6.161) were a survival prognosis factor. Multivariate analysis with a survival analysis (Cox’s Regression) shows CA-125 level (p=0.031, HR 4.131, CI 95% 1.143 – 14.933) and menarche (p=0.003, HR 4.989, CI 95% 1.736 – 14.342) were significantly related with survival prognosis in EOC (Epithelial Ovarian Cancer) patients at Dr. Sardjito Hospital.

Conclusion: CA-125 level affects the survival rate of epithelial ovarian cancer patients in Dr. Sardjito Hospital. Besides the level of CA-125, there are other factors that affect the survival rate of epithelial ovarian cancer patients which is the stage of cancer, residual operation and age of menarche.

Keywords: CA-125 level, EOC, prognosis, survival.


Keywords


CA-125 level; EOC; prognosis; survival

Full Text:

PDF


References

Berek JS, Fu YS, Hacker NF. 2002. Ovarian Cancer in Novak’s Gynecology 13th Ed, Williams & Wilkins, Pensylvania; 1245-1320.

Landis SH, Murray T, Bolden S, Wingo P. 1998. Cancer statistics. CA Cancer J Clin. 48: 6-30.

Sloan J, Schwartz A, Qureshi F, Jacques S, Malone J, Munkarah A. 2003. Ovarian Cancer: Change in patterns at diagnosis and relative survival over the last three decades, Am J Obstet Gynecol; 189: 1120-7.

Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. 2003. Survival and Prognostic Factor in Patients With Ovarian Cancer. ACOG; 101: 885-891.

Meyer T, Rustin GJ. 2000. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 82(9):1535-8.

Urban, N. 2003. Specific keynote: Ovarian cancer risk assessment and the potential for early detection. Gynecol. Oncol., 88(Suppl. 1), S75-S79. 7. American Cancer Society. How many women get ovarian cancer? Cited. 2004. February 22, available at www.cancer.org/docroot/CRI/content/CRI.

Hogdall, EV, Christensen L, Kjaer SK, Blaakaer L, Kjaerbye-Thygesen A, Gayther S, Jacobs IJ, Hogdall CK. 2007. CA 125 expression pattern, prognosis and correlation with serum CA 125 in ovarian tumor patients from the Danish “Malova” ovarian cancer study. Gynecol oncol. 104(3):508-17.

Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. 1995. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 86: 259-64.

Jacobs I, Bast RC. 1999. The CA125 tumourassociated antigen: a review of the literature. Hum Reprod. 4:1-12.

Boivin M, Lane D, Piche A, Rancourt C. 2009. CA125 (MUC 16) tumor antigen selectivity modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol. 115 (3): 407-13.

Munkarah AR, Hallum AV, Morris M, Burke TW, Levenback C, Atkinson EN. 1997. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol. 64:13-17.

Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Trope CG. 2012. Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV i a 20 year perspective. ACTA Obstet Gynecol Scan, 91:308-17.

Rodriguez M, Nguyen HN, Averette HE, Steren AJ, Penalver MA, Harrison T, Sevin BU. 1994. National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age. Cancer. 73: 1245-50.

Gocze P, Vahrson H. 1993. Ovarian cancer antigen (CA-125) and ovarian cancer (clinical follow-up and prognostic studies). Orv Hetil Hungarian. 134 (17): 915-8.



DOI: https://doi.org/10.22146/jkr.37949

Article Metrics

Abstract views : 3162 | views : 10088

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Jurnal Kesehatan Reproduksi



Jurnal Kesehatan Reproduksi Indexed by:

 

 



SEKRETARIAT JURNAL KESEHATAN REPRODUKSI
Departemen Obstetri dan Ginekologi, FK-KMK, UGM/RS Dr. Sardjito
Jl. Kesehatan No. 1, Sekip Utara, Yogyakarta 55281
Tlp: (0274) 511329 / Faks: (0274) 544003
Email: jurnal.kesehatanreproduksi@ugm.ac.id
Cp: Dwi Astuti +6281802698043